Iron

ApprovedSmall molecule

WWatson Pharmaceuticals

Iron is one of 408 small molecule programs targeting Uterine leiomyoma. It is currently in Approved.

Indications

Total Trials

Active Trials

407

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine LeiomyomaActive, not recruiting

Liver TransplantActive, not recruiting

Hip FractureNot yet recruiting

TachycardiaActive, not recruiting

MalariaActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

EndocarditisActive, not recruiting

AnemiaActive, not recruiting

Erythropoietic ProtoporphyriaActive, not recruiting

Vascular MalformationActive, not recruiting

Uterine LeiomyomaPhase 3

Active, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Hip FractureApproved

Not yet recruiting

TachycardiaPhase 1/Phase 2

Active, not recruiting

MalariaPreclinical

Active, not recruiting

Iron Deficiency AnemiaPhase 3

Active, not recruiting

EndocarditisPreclinical

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

Erythropoietic ProtoporphyriaPreclinical

Active, not recruiting

Vascular MalformationPhase 2

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Iron

WWatson Pharmaceuticals

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

LCZ696

Novartis

Preclinical

15 6

Monoferric

PPharmacosmos A/S

Preclinical

5 7

Savaysa

Daiichi Sankyo

Preclinical

—8

Zoloft

VViatris Specialty LLC

Preclinical

2 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Iron-Deficiency

NCT07197905

Q1 2027

Recruiting

Cardiac Surgery

NCT06637137

Q2 2027

Post-ApprovalRecruiting

Septic Shock

NCT06670963

Q3 2027

Post-ApprovalNot yet recruiting

Heart Failure

NCT06427200

Clinical

Trials by Indication[1]

Anemia6 trials

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Completed·WWatson Pharmaceuticals·Phase 2/3·NCT00223977·146 enrolled

Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty

Completed·FFederal University of São Paulo·Phase 3·NCT01857011·56 enrolled

Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency

Completed·CCasa Espirita Terra de Ismael·Phase 3·NCT01414374·50 enrolled

Show 3 more trials

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

Completed· Astellas logo

Astellas·Phase 3·NCT02278341·838 enrolled

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Completed·KKyntra Bio·Phase 2·NCT01414075·60 enrolled

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

Completed·AAmerican Regent, Inc.·Phase 3·NCT00396292·361 enrolled

Chronic Kidney Disease5 trials

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Completed· GSK logo

GSK·Phase 3·NCT02829320·28 enrolled

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Terminated·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT01155375·14 enrolled

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

Terminated·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT01155388·14 enrolled

Show 2 more trials

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients

Completed·—·Phase 4·NCT06556134·27 enrolled

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Completed·VVifor Pharma·Phase 3·NCT00994318·626 enrolled

Iron deficiency anemia5 trials

Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?

Completed·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·N/A·NCT00284700·260 enrolled

Iron Deficiency Anemia in Twin Pregnancies

Unknown status·SShengjing Hospital·Phase 4·NCT04975074·1,000 enrolled

The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant

Completed·—·N/A·NCT04101461·230 enrolled

Show 2 more trials

Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis

Unknown status·—·Phase 3·NCT05225545·30 enrolled

Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.

Unknown status·JJ. Uriach and Company·Phase 4·NCT00199277·150 enrolled

Intravenous2 trials

Intravenous High Dose Iron in Blood Donors

Completed·MMedical University of Graz·Phase 3·NCT01787526·176 enrolled

Efficacy of Treatment of Postpartum Anaemia With Intravenous Iron Versus Oral Iron in a Tertiary Hospital in South East, Nigeria.

Completed·FFederal Teaching Hospital Abakaliki·Phase 1/2·NCT07110935·290 enrolled

Dialysis Patients2 trials

Intravenous Versus Oral Iron Therapy in Hemodialysis Patients

Unknown status·—·Phase 3·NCT04464850·124 enrolled

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Completed·RRockwell Medical Technologies, Inc.·Phase 2·NCT01286012·108 enrolled

24 more indications

Hip Fracture2 trials

IV Iron in Association With Tranexamic Acid for Hip Fracture

Unknown status·IInstitut Kassab d'Orthopédie·N/A·NCT02428868·150 enrolled

IRONCARE: Iron Treatment in Older Patients With Hip Fractures - A Double-blinded Placebo-controlled Randomized Trial

Not yet recruiting·UUniversity of Aarhus·Approved·NCT07659184·528 enrolled

Fibromyalgia1 trial

A Randomized Trial of Oral Iron Therapy in Fibromyalgia

Completed·SSanjay Gandhi Postgraduate Institute of Medical Sciences·Phase 3·NCT01820052·120 enrolled

Infants1 trial

Supplementing Iron and Development in Breastfed Infants (SIDBI Study)

Unknown status·MMedical University of Warsaw·Phase 4·NCT02242188·220 enrolled

Septic Shock1 trial

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

Recruiting·PPiotr Czempik·Phase 4·NCT06670963·200 enrolled

Systolic Heart Failure1 trial

Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 4·NCT03036462·1,105 enrolled

Uterine leiomyoma1 trial

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

Withdrawn·WWatson Pharmaceuticals·Phase 3·NCT01553123

Pregnant Women1 trial

Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement

Completed·HHippocration General Hospital·Phase 1/2·NCT02957643·50 enrolled

Terminated·UUniversity of California, San Diego·Phase 2·NCT02564796·4 enrolled

Low Birth Weight1 trial

Iron Supplementation of Marginally Low Birth Weight Infants

Completed·UUmeå University·Phase 4·NCT00558454·380 enrolled

Inflammatory Bowel Disease1 trial

Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease

Unknown status·LLeiden University Medical Center·Phase 4·NCT05456932·90 enrolled

Tachycardia1 trial

Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

Terminated·MMayo Clinic·Phase 1/2·NCT01978535·3 enrolled

Efficacy and Safety1 trial

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Terminated· Sanofi logo

Sanofi·Phase 4·NCT00223938·112 enrolled

Gynecologic Cancer1 trial

Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

Completed·—·Phase 3·NCT01435200·64 enrolled

Malaria1 trial

RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants

Terminated·HHospital Clinic of Barcelona·N/A·NCT00497471·832 enrolled

Iron-deficiency1 trial

Restoring Iron Deficiency in POTS

Recruiting·VVanderbilt University Medical Center·Phase 2·NCT07197905·12 enrolled

Endocarditis1 trial

Management of Anemia in Patients with EndocaRditis Infectious Candidates for Cardiac Surgery: the AMERICA Study

Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT06583902·100 enrolled

Heart Failure1 trial

Efficacy and Safety of Lactoferrin in Heart Failure Patients

Not yet recruiting·—·Phase 4·NCT06427200·114 enrolled

Erythropoietic Protoporphyria1 trial

Oral Iron for Erythropoietic Protoporphyrias

Completed·IIcahn School of Medicine at Mount Sinai·N/A·NCT02979249·16 enrolled

Liver Transplant1 trial

.Patient Blood Management Program in Liver Transplantation

Unknown status·HHospital Universitari de Bellvitge··NCT05187637·66 enrolled

Congenital Heart Disease1 trial

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

Withdrawn·EEmory University·N/A·NCT00459225

Celiac Disease1 trial

Effect of Intravenous Iron Supplementation on Celiac Disease Remission in Patients With Iron Deficiency and Intestinal Villous Atrophy: a Randomized Trial

Terminated·AAssistance Publique - Hôpitaux de Paris·Approved·NCT05114278·1 enrolled

Postpartum1 trial

Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research

Completed·NNICHD Global Network for Women's and Children's Health·Phase 3·NCT05590260·4,857 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Iron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Watson Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWatson Pharmaceuticals

Iron

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Anemia6 trials

Chronic Kidney Disease5 trials

Iron deficiency anemia5 trials

Intravenous2 trials

Dialysis Patients2 trials

Hip Fracture2 trials

Fibromyalgia1 trial

Infants1 trial

Septic Shock1 trial

Systolic Heart Failure1 trial

Uterine leiomyoma1 trial

Pregnant Women1 trial

Cardiac Surgery1 trial

Vascular Malformation1 trial

Erythropoietin1 trial

Low Birth Weight1 trial

Inflammatory Bowel Disease1 trial

Tachycardia1 trial

Efficacy and Safety1 trial

Gynecologic Cancer1 trial

Malaria1 trial

Iron-deficiency1 trial

Endocarditis1 trial

Heart Failure1 trial

Erythropoietic Protoporphyria1 trial

Liver Transplant1 trial

Congenital Heart Disease1 trial

Celiac Disease1 trial

Postpartum1 trial

References

Drug Info

Quick Facts

Related News